CCCC vs ED · rev $35.6M vs P/E 18, rev $15.26B
C4 Therapeutics Inc (CCCC) versus Consolidated Edison Inc (ED) — a side-by-side from cached financials, not a winner call.
C4 Therapeutics Inc (CCCC) is a biotechnology company listed on US.
Consolidated Edison Inc (ED) is a utilities - regulated electric company listed on US.
Latest reported CCCC revenue for 2024-12-31 was $35.6M. Net income was -$105.3M. Revenue was up 71.4% from 2023-12-31 to 2024-12-31. CCCC currently screens at market cap $425.7M.
Latest reported ED revenue for 2024-12-31 was $15.26B. Net income was $1.82B. Revenue was up 4.0% from 2023-12-31 to 2024-12-31. ED currently screens at market cap $36.02B and trailing P/E 18.3.
CCCC currently screens at market cap $425.7M. ED currently screens at market cap $36.02B and trailing P/E 18.3.
Not investment advice. Open the CCCC and ED stock pages for the full models.
Not investment advice.